
Fibromyalgia and Overlapping Disorders: The Unifying Concept of Central Sensitivity Syndromes

Muhammad B. Yunus, MD

Objectives: To discuss fibromyalgia syndrome (FMS) and overlapping conditions, eg, irritable bowel syndrome, headaches, and chronic fatigue syndrome, within the concept of central sensitivity syndromes (CSS).

Methods: A critical overview of the literature and incorporation of the author's own views.

Results: The concept of CSS seems viable. It is based on mutual associations among the CSS conditions as well as the evidence for central sensitization (CS) among several CSS members. However, such evidence is weak or not available in other members at this time, requiring further studies. The biology of CSS is based on neuroendocrine aberrations, including CS, that interact with psychosocial factors to cause a number of symptoms.

Conclusions: CSS is an important new concept that embraces the biopsychosocial model of disease. Further critical studies are warranted to fully test this concept. However, it seems to have important significance for new directions for research and patient care involving physician and patient education. Each patient, irrespective of diagnosis, should be treated as an individual considering *both* the biological and psychosocial contributions to his or her symptoms and suffering.

© 2007 Elsevier Inc. All rights reserved. *Semin Arthritis Rheum* 36:339-356

Keywords: *fibromyalgia, central sensitivity syndromes, central sensitization, overlapping syndromes, fibromyalgia associations, functional syndromes*

Central sensitivity syndromes (CSS) comprise an overlapping and similar group of syndromes without structural pathology and are bound by the common mechanism of central sensitization (CS) that involves hyperexcitement of the central neurons through various synaptic and neurotransmitter/neurochemical activities (1,2). CS is manifested as hypersensitivity to various noxious (eg, pressure and heat) as well as nonnoxious (eg, touch) stimuli. Fibromyalgia syndrome (FMS) and similar conditions have been called "functional" (3), "functional somatic syndromes" (4), and medically unexplained symptoms (5), among others. None of these nomenclatures, however, clearly states 2 essential criteria of CSS, ie, an overlapping relationship between these syndromes and an appropriate pathophysiological mechanism (eg, CS) that is common to them. I have proposed CSS as a class terminology for these conditions (1,2) that seems rational and may explain several symptoms.

Besides a lack of structural pathology, the CSS diseases have several similar features in common, eg, pain, fatigue, poor sleep, sensitivity to noxious and nonnoxious stimuli, mutual associations, and the presence of psychosocial difficulties in a subgroup of patients. Many but not all patients with a CSS condition have psychological distress, so that CSS cannot be viewed as purely psychological or psychiatric in nature. For this essay, I shall use the terms disease and illness synonymously.

Current members of the CSS group are shown in Fig. 1. Interstitial cystitis (IC) has been included because of its close clinical similarity to female urethral syndrome (FUS), nonspecific bladder histology, presence of CS, and its association with other CSS members.

Other conditions not listed above, eg, premenstrual tension syndrome and vulvodynia, may also belong to the CSS spectrum on clinical grounds, but at this time they do not satisfy the 2 criteria mentioned above. Gulf war syndrome (GWS) has not been listed as a separate entity. It seems to be a mixture of several CSS conditions: FMS (6), chronic fatigue syndrome (CFS) (7), multiple chemical sensitivity syndrome (MCS) (7), posttraumatic stress disorder (PTSD) (8), and irritable bowel syndrome (IBS)

Professor of Medicine, Section of Rheumatology, The University of Illinois College of Medicine at Peoria, Peoria, Illinois.

There is no conflict of interest.

Address reprint requests to: M.B. Yunus, MD, Department of Medicine, University of Illinois College of Medicine at Peoria, One Illini Drive, Peoria, IL 61605. E-mail: yunus@uic.edu

0049-0172/07/\$-see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.semarthrit.2006.12.009

Abbreviations

AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate
CEP	cerebral-evoked potential
CFS	chronic fatigue syndrome
CNS	central nervous system
CRPS	complex regional pain syndrome
COMT	catechol- <i>o</i> -methyltransferase
CRH	corticotrophin-releasing hormone
CS	central sensitization
CSS	central sensitivity syndromes
D	dopamine
DNIC	diffuse noxious inhibitory control
EEG	electroencephalogram
FD	functional dyspepsia
f-MRI	functional magnetic resonance imaging
FMS	fibromyalgia syndrome
FUS	female urethral syndrome
GABA	γ -amino-butyric acid
GWS	Gulf war syndrome
HLA	human leukocyte antigens
HPA	hypothalamic-pituitary-adrenal
IBS	irritable bowel syndrome
IC	interstitial cystitis
MCS	multiple chemical sensitivity
mGlu	metabotropic glutamate
MPS	myofascial pain syndrome
NFR	nociceptive flexion reflex
NGF	nerve growth factor
NK1	neurokinin-1
NMDA	<i>N</i> -methyl- <i>D</i> -aspartate
PD	primary dysmenorrhea
PET	positron-emission tomography
PLMS	periodic limb movement in sleep
PMID	PubMed identification
PTSD	posttraumatic stress disorder
QST	quantitative sensory testing
RA	rheumatoid arthritis
REM	rapid eye movement
RLS	restless legs syndrome
RSTPS	regional soft-tissue pain syndrome
SLE	systemic lupus erythematosus
SP	substance P
TP	tender point(s)
TDS	time-dependent sensitization
TMD	temporomandibular disorders
Trk-B	tyrosine kinase B
TTH	tension-type headache
WDR	wide dynamic range

(8). Interestingly, visceral and cutaneous hypersensitivity were demonstrated in a subgroup of GWS patients with chronic gastrointestinal symptoms (9).

CS has been demonstrated in functional dyspepsia (FD) by gastric distension (10), and in vulvodynia (both locally and at distant sites) by pressure stimulus (11). FD is associated with IBS (12). Thus, FD is part of generalized gut sensitivity that also includes IBS, rather than being a separate CSS entity.

METHODS

This discourse is based on a critical overview of the literature (as of March, 2006) and an incorporation of the author's own ideas, insights, and opinions.

RESULTS

The Concept of Central Sensitivity Syndromes

To qualify for CSS membership, my conceptual paradigm includes (a) mutual associations between the CSS members; and (b) demonstration of CS to various stimuli among them (1,2).

Mechanisms of Central Sensitization

This section will provide only a general view of the CS mechanisms. For greater details the readers are referred to several reviews (13-15). CS is manifested by an abnormal and intense enhancement of pain by central nervous system (CNS) mechanisms.

Pain signaling involves activation of a variety of nociceptors at the periphery, in both somatic and visceral tissues. Such activation normally follows inflammation or trauma, even minor irritation (15) that releases inflammatory mediators, eg, bradykinin, serotonin, histamine, prostaglandin, and substance P (SP), among others. The peripheral nociceptive impulses travel through A-delta and C fibers to both nociceptive and wide dynamic range (WDR) neurons in the dorsal horn of the spinal cord. A-beta fibers carry nonnoxious impulses and both noxious and nonnoxious fibers converge in the WDR second-order neurons. Following a noxious stimulus, A-delta fibers carry sharp and well-localized pain known as first pain, whereas transmission of pain by C fibers is dull, diffuse, and burning, known as second pain. C fibers are involved in chronic pain.

WDR neurons respond to a range of stimulus intensities, from nonpainful (eg, gentle touch) to most painful. Thus, the WDR cells integrate input from converging nonnoxious A-beta, as well as noxious A-delta and C fibers. A-beta fibers, with proximity to noxious neurons in the area of WDR neurons, now become noxious in function, so that a normally nonpainful stimulus, such as touch or gentle pressure, is now perceived to be painful, a phenomenon known as allodynia. The postsynaptic fibers in the spinal cord then ascend to the thalamus, hypothalamus, the limbic system, and finally, the somatosensory cortex; these supraspinal structures are variously involved in the processing of different dimensions of pain, eg, sensory, evaluative, and affective (13-15).

The activated C-nociceptors express various neurotransmitters/neuromodulators at the afferent nerve terminals in the dorsal horn (Table 1). Following peripheral stimulation, these chemicals send a barrage of impulses and hyperexcite the postsynaptic neurons in the dorsal horn (mostly lamina I and II) where the afferent neurons terminate. Postsynaptic neurons bear certain receptors or




Figure 1 Currently proposed members of the CSS family with overlapping relationships and a common pathophysiological link of CS. IBS, irritable bowel syndrome; T-T headache, tension-type headache; TMD, temporomandibular disorders; MPS, myofascial pain syndrome; RSTPS, regional soft-tissue pain syndrome; PLMS, periodic limb movements in sleep; MCS, multiple chemical sensitivity; FUS, female urethral syndrome; IC, interstitial cystitis; PTSD, posttraumatic stress disorder. Depression may also be a member (see text). Modified from reference 198.

neuroeffector targets (Table 1). Neurokinin (NK)1 receptors are activated by SP; *N*-methyl-D-aspartate (NMDA), α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), and metabotropic glutamate (mGlu) receptors by glutamate; and tyrosine kinase B (Trk-B) receptors by nerve growth factor (NGF).

Opioid receptors are found in the copresence of SP receptors in the spinal cord, in both pre- and postsynaptic sites and other CNS sites (16). Thus opioid receptors seem important in attenuation of neurotransmission by SP. Opioids can also modulate NMDA receptor activity (16).

SP has an important role in pain transmission and its amplification, causing CS. It unmasks the silent receptors in the synapses that contribute to augmentation of second-order neuron excitability. Moreover, it can diffuse some distance to excite other neurons beyond its origin, contributing to an anatomical expansion of the pain area (ie, increased receptive field), which is characteristic of CS (14,15). The release of SP and other neurochemicals, eg,

NGF and glutamate, into the synapse causes synaptic hyperexcitability, which in turn removes the magnesium block of the NMDA receptor channel, allowing glutamate to activate the NMDA receptors on the postsynaptic neuron. Nitric oxide (NO) is also involved in NMDA receptor activation, which is vital to neurotransmission (14). Activation of the NMDA receptor is followed by an increased entry of intracellular calcium, membrane changes and activation of protein kinase, phospholipases, and nitric oxide synthetase (producing NO), as well as expression of *c-fos*, all of which contribute to a remarkable degree of CS (13-15). NMDA receptors seem mostly responsible for escalation of hyperexcitability of the second-order neurons. These phenomenal functional changes cause neuroplasticity, leading to excessive amplification of a peripheral stimulus, so that even an innocuous stimulus like touch is now perceived as painful.

Dopamine (D) also plays a role in CS. It has been shown that D_1 -like receptors (that include D_1 and D_5) increase nociceptive neuronal excitability (15,17),

Table 1 Neurochemicals and Neuroreceptors Involved in Central Sensitization

Neuromodulators/Neurotransmitters Released by Activated C-nociceptors Presynaptically	
Substance P (SP)	Somatostatin
Calcitonin-gene-related peptide (CGRP)	Galanin
	Never growth factor
	Glutamate
Vasoactive intestinal peptide (VIP)	Aspartate
Post Synaptic Neuroreceptors/ Neuroeffector Targets	
Neurokinin 1 (NK1)	Metabotropic glutamate (mGlu)
N-methyl-D-aspartate (NMDA)	Tyrosine kinase B (Trk-B)
Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)	Protein kinase gamma (PKC-gamma)
	Vanilloid subfamily (TRPV-1, TRPV-1)

whereas D₂-like receptors (that include D₂, D₃, and D₄) inhibit it (15,18). In support of this, pramipexole, a D₃ agonist, has been shown to be effective in fibromyalgia in a randomized double-blind controlled study (19). Studies have demonstrated a role for ion channels (13,14) and cytokines released from microglia and astrocytes in the nervous system in generation of pain following an inflammatory or traumatic stimulus (14).

Windup is a progressive increase in pain perception with second-order neuronal response to repetitive stimulation (more often than every 3 seconds) of peripheral C fibers. This phenomenon, known as temporal summation (or summation) in humans, occurs in parallel to CS (14). Temporal summation involves the production of second pain, which is described as dull or burning, and leaves an after-stimulus unpleasant sensation. It is generally agreed that NMDA receptors mediate summation, and it can be inhibited by NMDA receptor antagonists, eg, ketamine (20), which may be relevant in treating chronic pain.

CS is clinically and physiologically characterized by hyperalgesia (excessive sensitivity to a normally painful stimulus), allodynia, expansion of receptive field (that is likely to explain widespread pain), a prolonged electrophysiological discharge (that may explain the chronic nature of pain), and an after-stimulus unpleasant pain (eg, burning, throbbing, and paresthesia) that lasts longer than that observed in normal controls following a noxious stimulus (13-15). Because of the remarkable overall hyperexcitement of the central neurons, CS may explain the hypersensitivity to many environmental (eg, noise, weather, stress) and chemical (eg, pesticides and medications) stimuli. CS becomes self-sustained without further stimuli, even minor, because of long-term CNS neuroplasticity, and is probably accentuated with chronicity in human diseases.

CS is dampened by the body's intrinsic mechanism of

pain inhibition. Several descending pathways from the cortico-reticular system, locus ceruleus, hypothalamus, brain stem, and local spinal cord interneurons utilize neurotransmitters that include serotonin, norepinephrine, γ -amino-butyric acid (GABA), enkephalins, and adenosine (13-15). Evidence suggests that 5-HT₃ subtype has a facilitatory function, whereas 5-HT_{1A} receptor is inhibitory (15). Inhibition of the inhibitory function of 5-HT_{1A} augments CS in the dorsal horn, resulting in hyperalgesia and allodynia (15,18). The ascending and descending pathways do not have dichotomous functions, rather they are interactive and their functions are bidirectional; both pathways have the property of both facilitating and inhibiting pain, depending on the site of action and subtypes of a neurotransmitter.

The affective dimension of pain, eg, unpleasantness and emotional reaction, is mediated by spinal pathways to limbic structures and medial thalamic nuclei, and by anterior insular cortex, anterior cingulate cortex, and the somatosensory cortical areas (21).

Mutual Associations Among CSS Conditions

The initial report of an association between FMS, IBS, tension-type headache, and migraine using normal controls (22) has subsequently been confirmed by a large number of studies in the past 25 years using both normal and chronic pain (with structural pathology) controls (2,23-62), as reviewed by Aaron and Buchwald (23), and more recently by Yunus (2). Variations in the prevalence of several CSS members are most likely due to different methodology, including different criteria used, but these prevalences, irrespective of use of controls, seem much higher than those found in available population studies. A few studies were not referenced in the Reference section because of page limitation, small N, or otherwise unsatisfactory methods, but most of these are referred by their PubMed identification (PMID) numbers at the footnote of Table 2.

Evidence for Central Sensitization Among CSS Members

CS by peripheral stimuli has been documented in a majority of patients with a CSS condition as compared with normal controls (Table 3). Selected references will be provided here, and others will be indicated by their PMID numbers in the footnote of Table 3.

Fibromyalgia Syndrome

All patients with FMS have generalized exaggerated pain response by digital pressure (CS). Nondigital pressure, eg, by dolorimeter or palpometer, has also been applied to demonstrate hyperalgesia (63-72). Most of these studies have tested multiple modalities of stimuli besides pressure, eg, heat, cold, and electric, by quantitative sensory testing (QST).

Table 2 Mutual Associations Among Central Sensitivity Syndromes (CSS) members: Significantly Greater Prevalence of a CSS Member Among Other CSS Conditions*

CSS Condition Studied	Mean Prevalence (%) of Another CSS Member Among the Conditions Studied [range]	Total # of Studies (# with a control group)†	Total N of Patients from all Studies	References‡	
FMS	CFS 39 [22–74]	6 (3)	214	24–29	
	IBS 45 [32–70]	17 (13)	1,776	22,25,27 30–40	
	TTH 42 [22–60]	6 (4)	889	22,27,33 39–41	
	Migraine 38 [22–48]	3 (1)	183	22,25,41	
	UHA 50 [35–56]	5 (2)	558	30,31,34	
	TMD 50 [24–75]	2 (1)	82	27	
	RLS 31	1 (1)	135	42	
	PLMS 38	1 (1)	16	43	
	MCS 36 [18–55]	3 (1)	104	27,29,44	
	PD 48 [45–50]	2 (2)	103	33,40	
	FUS 15 [12–18]	2 (2)	262	45,46	
	IC 8	1 (1)	22	27	
	PTSD 57	1 (0)	77	47	
	CFS	FMS 48 [16–80]	2 (2)	57	27,29
		IBS 36	1 (1)	25	27
UHA 87		1 (0)	236	48	
TMD 28		1 (0)	25	27	
IBS	FMS 36 [28–65]	5 (4)	179	25,38,49	
	CFS 14	1 (0)	200	50	
	UHA 42 [31–50]	3 (3)	297	51–54	
	PD 68	1 (0)	100	51	
Migraine	CFS 51	1 (0)	63	54	
	RLS 34	1 (0)	50	55	
TMD	FMS 13 [9–18]	3 (2)	104	27,56	
	IBS 16	1 (1)	25	27	
	TTH 23	1 (1)	25	27	
	IC 17	1 (1)	25	27	
MCS	FMS 49	1 (0)	100	57	
	CFS 59 [30–88]	2 (0)	130	26,57	
	UHA 63	1 (0)	30	26	
IC	FMS 15 [12–17]	2 (1)	2,435	58,59	
	IBS 50	2 (1)	2,445	58,60	
PTSD	FMS 20 [19–21]	2 (2)	295	61,62	
	IBS 37	1 (1)	266	61	

*CFS-chronic fatigue syndrome; FMS-fibromyalgia syndrome; FUS-female urethral syndrome; HA-headache; IC-interstitial cystitis; MCS-multiple chemical sensitivity; PD-primary dysmenorrhea; PLMS-periodic limb movements in sleep; PTSD-post-traumatic stress disorder; RLS-restless legs syndrome; TMD-temporomandibular disorder; TTH-tension-type headache; UHA-unspecified headache.

†The prevalence of a CSS condition in uncontrolled studies were higher or much higher than that reported in general population.

‡Studies with first author (PMID#) that were not referenced in the table, but counted in the total N are: (1) FMS/IBS—Campbell SR (6347207); Veale D (2049586); Yunus MB (3171051) (2) FMS/UHA—Okifuji A (10593628); Yunus MB (3171051) (3) IBS/FMS—Veale D (2049586); Lubrano E (11515679) (4) TMD/FMS—Plesh O (8923373). Please note that space limitations do not allow listing of all the references in Table 2 and under References.

Fibromyalgia patients are hypersensitive to heat (64-66,68,72-77), cold (64-66,68,75,76), cutaneous electric (66,69,78), intramuscular electric (69,70), sural nerve electric (to assess nociceptive spinal reflex) (64,79), ischemic (65), and intramuscular hypertonic saline (69,70). Further, allodynia to warmth (68,73), cold (66,68), and pressure (73) has been documented. Temporal summation has been demonstrated by using heat (73,76), cold (74), and intramuscular electric (69) stimuli. Sensitivity to noise, as often complained by FMS patients, has been

demonstrated in a human pain laboratory by using a noise generator (67).

Augmented pain sensitivity has been reported in FMS by objective functional magnetic resonance imaging (fMRI) findings in response to peripheral stimuli by pressure (80) and both noxious and innocuous heat (81). A recent study showed a lack of inhibitory control in the brain to nonpainful repetitive somatosensory stimuli (by examining event-related potentials recorded by electroencephalogram (EEG) (82)), suggesting CS.

Table 3 Evidence for Central Sensitization by Controlled Studies in Selected Members of the CSS group in Response to Various Peripheral (Somatic) or Rectal (Visceral) Stimuli*

Stimulus	FMS	CFS	IBS	TTH	Migraine	TMD	MPS/RSTPS	PD
	# of studies (N of patients) [†]							
Pressure (somatic) [‡]	15 (580)			4 (178)	3 (117)	2 (42)	9 (462)	1 (20)
Pressure (rectal) [§]			26 (822)					
Heat (somatic)	12 (480)		2 (21)	1 (50)	3 (117)	3 (76)	3 (137)	2 (42)
Heat (rectal)			1 (46)					
Cold (somatic)	8 (255)		1 (33)		1 (41)		2 (184)	
Electric (cutaneous)	4 (61)		1 (12)				2 (36)	
Electric (intra-muscular)	2 (41)	1 (23)					2 (36)	1 (10)
Electric (spinal Reflex)	2 (107)		1 (14)	1 (40)			1 (27)	
Electric (rectal)			2 (21)					
Ischemic	1 (60)					2 (72)		
Hypertonic saline	2 (41)					1 (22)	1 (11)	
Auditory stimulus	1 (20)		1 (15)		1 (65)			

*See text for other evidence of CS (e.g. allodynia and temporal summation) in a CSS member, as well as evidence for CS in other CSS members. MPS/RSTPS-myofascial pain syndrome/regional soft tissue pain syndrome. See Table 2 for other abbreviations.

[†]Studies in all CSS conditions with first author (PMID#) that were not referenced in the text but counted for N in Table 3 are: (1) FMS/somatic pressure—Kosek E (9106808); Bendtsen L (9008605); Marques AP (1566761); Mikkelsen M (1514890); Staud R (15890634) (2) FMS/somatic heat—Kosek E (9106808); Berglund B (11932073) (3) FMS/Cold—Kosek E (9106808); Berglund B (11932073) (4) FMS/cutaneous electric—Arroyo JF (7848390) (5) IBS/rectal pressure—Greenwood B (8907258); Bernstein CN (8880836); Drewes AM (11495078); Fukudo S (12572883); Kwan CL (15621377); Chun A (1008061); Caldarella (15667496) (6) Migraine/pressure and heat—Kitaj MB (16109112) (7) MPS/somatic pressure—Giesbrecht RJ (16180957). Please note that space limitations do not allow listing of all references in the text and under References.

[‡]By non-digital pressure.

[§]By balloon.

The issues of dependence on patients' verbal response to a noxious stimulus (hence subjective in nature) as well as response bias are often raised, particularly in the legal setting. A local spinal reflex, called nociceptive flexion reflex (NFR), can be demonstrated by electrically stimulating the sural nerve directly and measuring the electromyographic response of the biceps femoris. It is a valuable objective test of CS since it bypasses the peripheral nociceptors and does not require a subject's oral response to a stimulus, and is mediated by central neurons. An accentuated NFR has been demonstrated in FMS (64). Using heat and pressure stimuli in both ascending and random paradigms, it has been shown that response bias (eg, expectancy and hypervigilance) does not play a major role in the report of pain by QST by fibromyalgia patients (72).

Chronic Fatigue Syndrome

One controlled study of 21 patients with CFS, of whom 48% had myalgia, demonstrated hypersensitivity to electric stimulus in widely distributed muscles, but not in the overlying skin or subcutaneous locations, irrespective of the presence or absence of myalgia (83). Several brain imaging studies in CFS have shown decreased blood flow in different regions of the brain, eg, frontal, parietal, temporal, subcortical, and periventricular (84). The significance of these findings is unknown but the regions involved may play a role in modulating fatigue and pain in CFS.

Irritable Bowel Syndrome

Evidence of CS to somatic (skin) and visceral (rectal) stimuli in selected studies of IBS is shown in Table 3. With most stimuli there was diffuse spread of pain beyond the rectal area to lower abdomen and lower back with persistent unpleasantness, 2 markers of CS. Most studies have used rectal balloon pressure as a stimulus (10,85-102). CS was demonstrated using other rectal stimuli as well, eg, heat (95) and electric (90,99). Both rectal (88) and cutaneous (91) allodynia has been demonstrated in IBS. Similar to generalized hyperalgesia and allodynia in the somatic peripheral tissues in FMS, there is a global gut hypersensitivity in IBS that involves the stomach (10,100) and the esophagus (101). Patients with functional dyspepsia demonstrated both esophageal and rectal hypersensitivity (10). Initially it was thought that cutaneous hyperalgesia is absent in IBS (99). However, subsequent studies have established excessive sensitivity of the skin to heat (191,103), cold (100), and electric (99) stimuli, mostly in conjunction with rectal hyperexcitability, even in the absence of concomitant FMS (103). Such visceral as well as somatic sensitization in the same patient is supportive of the concept that CSS may represent both somatic and visceral hypersensitivity. Interestingly, there is enhanced sensitivity of hand-forearm veins to distension produced by injection of hypertonic saline into the antecubital vein of migraine sufferers, representing another example of visceral hypersensitivity (104).

Hypersensitivity to noise, tested in human pain labo-

ratory (105), and the objective test of CS by facilitated spinal NFR (102) have been demonstrated in IBS similar to FMS. By applying sensory decision theory (that allows discrimination between sensory experience and response bias), it was shown that there was no response bias among the IBS patients (98). Brain imaging studies by fMRI and ¹⁵O-water positron-emission tomography (PET) following rectal or cutaneous stimulation have been reported (106) in support of CS/central pain in IBS.

Tension-type Headache

CS in tension-type headache (TTH) has been demonstrated in both cranial and extracranial sites in response to peripheral pressure (107-110), and heat (108) stimuli and by a facilitated spinal NFR (111). CS was also shown by qualitatively altered nociception (112), greater response to cerebral-evoked potential (CEP) (113), and a deficient pain inhibitory response by diffuse noxious inhibitory control mechanism (DNIC) (114) also demonstrated CS. However, a lack of CS has also been reported by cutaneous heat (113) and cutaneous electric stimuli (115).

Migraine

Enhanced sensitivity in migraine has been demonstrated in both cranial and extracranial (eg, hands) sites in response to mechanical (116,117), heat (116,117), cold (116), and CO₂ laser (118) stimuli. Hypersensitivity to sound (119) and light (120) has also been shown in the human pain laboratory. Other evidence for CS in migraine includes cutaneous allodynia in periorbital as well as forearm areas (116), summation to mechanical stimulus (117), and increased amplitude of cortical response to CO₂ stimulus (118). There is also venous hypersensitivity in migraine in the hand-forearm veins (a location away from the head) (104) as stated earlier. These observations of both somatic and visceral sensitivity in the same CSS condition (eg, migraine and IBS) raise an interesting possibility that CSS may represent a “pantissue sensitization.”

Temporomandibular Disorders

Temporomandibular disorders (TMD) represent a heterogeneous group of disorders in patients with or without structural pathology. Only the myofascial variety by Research Diagnostic Criteria (RDC) (121) is included here as a member of CSS. Hyperresponsiveness to pressure (122,123), heat (124-126), ischemia (124,127), and hypertonic saline (123) has been recorded in both facial and extracranial sites, along with summation to thermal stimulus (125,126). One study failed to show hypersensitivity to heat (123). Most interesting is the description of a patient who demonstrated many features of CS in response to nonnoxious vibrotactile stimulus in the arm and face, eg, unpleasantness of evoked pain that lasted 30 minutes, temporal summation, and allodynia; allodynic

pain decreased following administration of the NMDA receptor antagonist dextromethorphan using the vehicle as a control (126).

Myofascial Pain Syndrome/ Regional Soft-Tissue Pain Syndrome

We (128) and others (129) have questioned the current construct of chronic myofascial pain syndrome (MPS). Here I shall use the terms chronic “regional soft-tissue pain syndrome” (RSTPS) and MPS synonymously to include a regional chronic pain condition with TPs in the absence of structural pathology.

To qualify for CS in RSTPS/MPS, hypersensitivity to a stimulus needs to be demonstrated at both symptomatic and distant sites. Such an exaggerated response has been demonstrated to pressure (63,78,130-135), heat (131-133), cold (131,134), electric (78,132,135), and vibration (131). An accentuated spinal NFR (ie, a decreased threshold to electric stimulus) (135) and allodynia (131) have also been documented. One study, however, showed increased pain threshold to thermal stimulus (132). By fMRI, Giesecke and coworkers showed extensive cortical activation suggestive of augmented central pain processing in RSTPS (136), similar to FMS (80).

Restless Legs Syndrome

In the restless legs syndrome (RLS), punctate mechanical stimulation by pin prick showed a significant generalized hyperalgesia in both upper and lower extremities (137), and electric stimulation of the medial plantar nerve demonstrated increased excitability of the spinal NFR with spatial spread (138). Two transcranial magnetic stimulation studies exhibited decreased inhibition (and increased facilitation) of the central motor pathways (139,140).

Multiple Chemical Sensitivity

It has been theorized that MCS is based on a time-dependent sensitization (TDS) model that involves sensitization of the CNS (141). Repeated environmental exposures to a low-level chemical (or a large single exposure) produces CS to that chemical, particularly involving the limbic system, in susceptible individuals. A progressive amplification of the sensitivity to that chemical then occurs with repeated exposure, reminiscent of summation. Eventually the sensitization becomes self-sustained, so that re-exposure even to a minute amount of the chemical manifests the symptoms of severe sensitization. Evidence of CS to sensory stimuli by QST and other methods is lacking, except that greater noise sensitivity has been demonstrated (141). Studies of CS similar to other CSS members are strongly suggested in MCS.

Primary Dysmenorrhea

Several QST studies have been performed in patients with dysmenorrhea, presumably of the primary type. These

studies have compared pain sensibility to various stimuli across different phases of the menstrual cycle comparing dysmenorrheic and nondysmenorrheic patients. Dysmenorrheic patients showed decreased pain threshold to pressure (142), heat (142,143), and electricity (144) in the abdomen, back, and extremities, in a given menstrual phase, suggesting the CS threshold to cold pressure stimulus was increased (145), but tactile sensation was normal (142). One study showed increased amplitude by CO₂ laser-evoked cerebral potential (143).

Interstitial Cystitis

Greater sensitivity to somatic pressure in muscles, bladder distension by normal saline, as well as ischemic stimulus (by ischemic forearm test) was demonstrated in 1 study involving 13 patients and 13 healthy controls (146).

Posttraumatic Stress Disorder

It has been hypothesized that the underlying mechanism of sensitization in PTSD is similar to TDS, except that it is the emotional stress (instead of chemical) that causes sensitization by a single severe exposure or repeated ones to various stresses, eg, war, torture, childhood abuse, rape, natural disasters, and terrorist attacks (147). Startle reflex (by a loud auditory tone or noise and manifested by eye blinking and increased heart rate) is exaggerated in PTSD (148). The startle response may reflect a progressive CNS neuronal sensitization following stress (148). Cerebral blood flow studies by PET have shown increased activation of the amygdala with fear acquisition and lack of activation of the cingulate cortex (149). Studies of CS by QST and other relevant methods are greatly needed in PTSD.

Depression and Central Sensitization: Is Depression a Member of the CSS Spectrum?

The association between chronic pain disorders (including the CSS diseases) and depression is so well established that providing a large list of references would be superfluous. Prospective studies suggest that the relationship is bidirectional: chronic pain predicts depression (150) and major depression predicts chronic pain (151). A majority of patients with depression also complained of chronic pain (152). Intriguingly, patients with depression had *higher* pain thresholds than controls despite much pain. The number of TPs in depression was significantly *lower* than that in fibromyalgia (153). In the human pain laboratory, pain perception and threshold were mostly *increased* in patients with depression by most stimulus modalities, as critically reviewed by Dickens and coworkers (154). Decreased pain sensitivity has been demonstrated to several modes of stimuli, eg, pressure (155,156), heat (155,156), and cutaneous electric (156). On the other hand, ischemic stimulus produces decreased pain toler-

ance or threshold (157,158). All patients studied had major depression except minor depression in 1 study (157).

Besides the stimulation types, laterality seems to play a major role in sensitization in major depression. The left side of the body is more reactive to pain stimuli in depression (156,159). This would support the theory that negative affect activates the right cerebral hemisphere that, in turn, potentiates further adverse stimuli, including pain, thus integrating depression and pain in depressed patients (160). A cerebral blood flow study showed asymmetry in the anterior cingulate and prefrontal regions with lower activity in the left hemisphere in depression (160), indirectly supporting an active role for the right hemisphere in depression, as also noted by others (156).

In summary, the relationship between pain and depression is complex that is influenced by many factors, eg, mode of stimuli, laterality, gender, type of depression (eg, unipolar versus bipolar, acute versus chronic), emotional status, and status of medications at the time of the study (156).

I think the pain–affect relationship in depression is mediated by CS that is different from other CSS members. Thus, activation of certain right hemispheric regions may produce sensitization for negative affect (“negative sensitization”) and negative effects, eg, pain, causing greater pain sensitivity on the left side. Negative emotional stimuli (eg, stress associated with childhood adverse experiences) may activate the right hemisphere and cause comorbid depressive illness and pain. Moreover, it is possible that the right hemispheric activation/sensitization may preexist because of genetic susceptibility.

Can depression be classified as a CSS member? Depression is associated with all the CSS diseases. There is evidence of CS in depression, although CS is limited to ischemic stimulus (157,158), and unlike other CSS members, there is *decreased* sensitivity to pressure, heat, and cutaneous electric stimuli. There is significant coaggregation of major depression with several CSS conditions among the first-degree relatives of patients with major depressive disorder (161), and there is similar coaggregation of depression among the first-degree relatives of patients with fibromyalgia (162). Thus, it would seem that depression may belong to the CSS groups of diseases, but further studies will be needed.

It must be cautioned that depression and CSS disorders are not the same disease (overlap does not mean total overlap). Several studies have shown that the biology of depression is different from that in fibromyalgia. As examples, sleep EEG typically shows rapid eye movement (REM) abnormalities in depression (163) as opposed to non-REM sleep abnormalities in fibromyalgia (164). The dexamethasone test shows nonsuppression in major depression (165) as compared with mostly normal suppression in fibromyalgia (166). The hypothalamic-pituitary-adrenal (HPA) axis is hyperactive with hypercortisolemia in depression (167) as opposed to relative hypocortisolemia in fibromyalgia (166,168). Findings similar to fibro-




Figure 2 Simplified suggested biopsychosocial mechanisms for CS and CSS with interacting factors. ANS, autonomic nervous system. The relationship between central sensitization and CSS may be bidirectional; chronicity of CSS may accentuate central sensitization.

myalgia and different from depression have been observed in other members of CSS as well, including alpha-delta sleep (169) and enhanced cortisol suppression by the dexamethasone test (170) in CFS, and normal dexamethasone test results and blunted cortisol response to corticotrophin-releasing hormone (CRH) in IBS (171).

Studies on anxiety are limited. In panic disorder, 2 studies showed normal responses, 1 to pressure, cold, and heat stimuli (155), and the other to electric stimulus (172). Whether psychiatric disorders should be included in the CSS spectrum is quite unresolved at this time, and further studies will be needed to answer this question.

Factors That May Contribute to, or Trigger, Central Sensitization

A suggested simplified schema of various factors that may contribute to CS and CSS is shown in Fig. 2.

Genetic Contribution

Pain in general is known to be modulated by genetics (173). In FMS, reduced pressure pain threshold aggregate

in first-degree relatives of FMS patients, even among those without symptoms (162,174).

Genetic factors in CSS are present in virtually all its members as demonstrated by twin, family, and molecular genetic studies. CSS diseases are polygenetic and are importantly influenced by environmental factors. Genetic markers related to serotonin, dopamine, catechol-*O*-methyltransferase (COMT), and human leukocyte antigens (HLA) have been found in FMS, as reviewed by Buskila and coworkers (175). T102C polymorphism (of the 5-HT_{2A} receptor) was associated with FMS (176), IBS (177), TMD (178,179), and migraine (179). The COMT gene predicted TMD (180). The T/T genotype showed an association with severity of pain in FMS (176). Serotonin transporter gene polymorphism was reported in FMS (175), IBS (181), TTH (182), migraine (179), CFS (183), and depression (184). CFS was associated with HLA class II alleles (185) and PTSD with dopamine transporter gene (186). Linkage with HLA (187,188) and 5-HT_{2A} receptor (188) genes in FMS, and with 12q and 15q loci 9 (189) in RLS has been demonstrated.

Autonomic Nervous System

Sympathetic overactivity (often associated with sympathetic hypoactivity in response to stressors) or parasympathetic underactivity, mostly measured by spectral analysis of heart rate variability, has been reported by several studies in FMS (190), IBS (191), CFS (192), and RLS (193). Increased sympathetic activity may be related to CS, as exemplified by complex regional pain syndrome (CRPS) (194), which is characterized by severe chronic pain and allodynia symptoms. There is CS in CRPS, with hyperalgesia and summation (195). Martinez-Lavin (196) suggests that sympathetic overactivity may not only cause diffuse pain, but also contribute to other symptoms of CSS, eg, poor sleep (due to sustained nocturnal sympathetic activity) and fatigue (due to deranged sympathetic response to stress).

Neuroendocrine Dysfunction

HPA axis dysfunction with mild or relative hypocortisolism is common to many CSS members, eg, fibromyalgia, CFS, chronic headaches, and PTSD (197). Based on animal and human data, Heim and coworkers suggest that a state of hypocortisolism and perturbed HPA axis resulting from early childhood and other stresses increases the vulnerability for developing CSS in the future, and that it is not due to the effect of chronic pain (197). The relationship between low cortisol and CS is currently uncertain, but it is possible that there is an interaction between them involving the stress mechanism.

Psychological Factors

Most studies show that anxiety, stress, depression, and other psychological problems are significantly more common in CSS conditions than controls in a subgroup of patients (48,198-203), with a bidirectional relationship (150,151,197). Stress plays an important role in the CSS disorders (197). However, data are sparse regarding the contribution of psychological distress to CS.

In healthy individuals, anxiety predicted temporal summation by heat stimulus (204). A correlation exists between anxiety and pain symptoms in population studies, but none by electric stimuli (205). CS evaluated by manual tender point (TP) examination correlated with psychological distress including anxiety, depression, and ill-health behavior in FMS (206,207). However, such a correlation was absent in other studies (208,209).

In FMS, catastrophizing was related to decreased pain threshold and tolerance to heat stimulus (73) and to increased activity in brain areas related to anticipation, attention, and the emotional aspects of pain, as shown by fMRI in response to pressure stimulus delivered by a rubber probe (210). Thus, psychological factors may play an important role in pain perception and pain processing in FMS. However, in IBS, pain sensitivity by rectosigmoid distension was not correlated with psychological distress

(86). An association has been shown between childhood abuse and CSS conditions, eg, FMS and CFS (211), IBS (212), and headaches (213). Childhood adverse experiences may promote long-lasting neuronal plasticity that causes both physical and psychological symptoms, as well as CS among the adults.

Only a few studies assessed a relationship between childhood abuse and CS. Among healthy individuals, there is a decrease in pain sensitivity to heat and ischemic stimuli despite much pain complaints and negative affect (214). A history of adverse childhood experiences was associated with high TP counts in FMS in a population study (207), and low pain threshold in IBS by digital pressure at the periphery (212). However, there was an increased pain threshold to balloon pressure in IBS (215) and an increased pain tolerance to ischemic pain in TMD (216). The paradox between increased pain symptoms and decreased pain sensitivity in the laboratory setting among the abused patients may be explained by a psychological barrier to sharply painful stimuli in an experimental laboratory setting that may trigger a painful memory (215).

Infection, Inflammation, Trauma, Sleep, and Environmental Factors

General viral (48,217) or local (218) infections, as well as trauma (133,135), are reported to trigger many CSS conditions, probably through the action of inflammatory mediators that activate nociceptive fibers with resultant CS. However, there is no ongoing peripheral inflammation in FMS (219). The role of afferent neurons in CSS needs further study. A review article concluded that trauma from motor vehicle accidents (MVA) may trigger FMS in the presence of preexisting psychological vulnerabilities, and that there is a causal relationship between FMS and MVA (220), but another study failed to find an association between MVA and FMS (221). This latter article, however, has certain drawbacks, eg, a majority (60%) of the patients were male and no psychological factors were measured (221).

CS has been demonstrated in osteoarthritis (222), and several systemic diseases, eg, rheumatoid arthritis (RA) (223) and systemic lupus erythematosus (SLE) (224,225), are associated with FMS. It is possible that arthritis (222-225) or colonic inflammation (226) activates local nociceptors that initiate or sustain CS, particularly in susceptible individuals. However, other unknown shared neuroendocrine and genetic mechanisms may be involved.

Nonrestorative sleep may cause CS. Healthy individuals subjected to disturbed sleep in a sleep EEG laboratory demonstrate multiple TP that were absent at baseline before sleep deprivation (164). Moreover, CS by algometry and other nociceptive stimuli (71,76,227) is correlated with poor sleep. Environmental stimuli, eg, noise, may

also induce CS in the experimental pain laboratory (67,99,148).

DISCUSSION

Historically, the concept that several CSS disorders are interconnected was first published in 1984 (228) based on the previous demonstration of associations of several CSS members with FMS (22). Fifteen years ago, attention was drawn to the fact that the pathophysiology of FMS involves aberrant central pain mechanisms (229). Now it seems likely that a major component of the central pain mechanism is CS, and it is a major binder for the CSS conditions. At this time, evidence for CS is not present in all patients of the CSS family (similar to other diseases, eg, the HLA marker in spondyloarthropathies). Based on good and converging data, there is evidence for CS in FMS, IBS, MPS/RSTPS, and migraine, while modest evidence is present in TMD, RLS, and primary dysmenorrhea (PD) that require further study. Data are limited or not published for other members, eg, MCS, TTH, PTSD, CFS, and IC. However, restating a cliché, absence of proof does not mean absence; rather, proper studies addressing an array of methodological issues (see below) have not yet been performed.

The literature shows that the demonstration of CS will depend on numerous factors, many of which have not been addressed in currently available studies. A large number of elements that may affect CS include host factors (age, gender, genetics, interindividual variation in pain response), uniformity of disease classification, subgroups (eg, those with psychological distress), measurement of pain perception, threshold or tolerance, stimulus types (digital palpation, algometer, heat, electricity, ischemic, phasic versus tonic, ascending versus random, etc), sites tested, technique, and methods used (including QST, CEP, and brain imaging), types of tissues stimulated (eg, skin, subcutis, muscle, viscera), and treatment status among others. Thus, some patients not showing CS may do so if the above variables are taken into consideration. Response variability based on types of stimuli and types of tissue tested is well documented (65,66,68,69,117,123). Heat stimulator excites surface receptors, whereas cold pressor test affects deeper tissues (65). Pressure pain threshold was decreased but threshold to cutaneous electric stimulation was normal in FMS (69). Also in FMS, heat perception was normal, but heat threshold was decreased (64). These variabilities may also influence a correlation between CS and clinical or psychological symptoms.

CS is correlated with several symptoms, eg, pain (64,96,130,133,206,230), poor sleep (71,206,230), fatigue (206,207,230), and associated psychological factors (206,207,230). However, some studies failed to show a significant correlation between CS and spontaneous pain (65,66,102). This is hardly surprising considering the numerous complex factors that determine CS, as mentioned

earlier, as well as the momentary nature of pain elicited in the laboratory as contrasted with chronic pain for months or years. The correlation between FMS symptoms and CS is stronger when CS is measured by TP examination, as compared with dolorimetry (65,206). TP assessed by digital pressure also shows greater correlation with psychosocial factors in comparison with dolorimetric pressure (206). It would seem that different biopsychopathology is involved in different modalities of stimuli and they do not clinically measure the same thing. At this time, there are only limited, and often contradictory, data on the relationship between CS and psychosocial factors as well as psychiatric diseases, as stated above. Given the complex and multiple facets of both CS and psychosocial factors, further studies are warranted.

CS is probably a preexisting phenomenon that may be present in asymptomatic individuals before developing symptoms and is likely to play a causative role in CSS, probably with other risk factors, eg, genetics. This view is suggested by the following: (a) the greater likelihood of asymptomatic subjects with genetically determined hypersensitivity to thermal and ischemic stimuli to develop TMD on follow-up than those without enhanced sensitivity (180); (b) the increasing degree of CS (as measured by number of TP) exists as a continuum among asymptomatic subjects, those with regional pain, and patients with widespread pain (63,65,206,207,230); (c) the presence of CS in asymptomatic first-degree relatives who are highly likely to develop a CSS condition in the future (162,174); and (d) the attenuation of CS by drugs (70,231-234) that also ameliorate symptoms during the study period (70,231-233). Thus, CS may be the cause rather than the effect of CSS diseases.

Given a correlation between CS and symptom duration (63), the relationship between CS and CSS may be bidirectional, ie, CS causes CSS, and the chronicity of CSS disease may further accentuate CS. A schematic representation of probable contributory factors of CS that may lead to CSS is shown in Fig. 2. Since psychosocial factors contribute to CS, consideration of these factors is very important in the management of CSS disorders that should involve a person-centered approach (235).

CS may not be the only mechanism causing symptoms in CSS disorders. Genetics, poor sleep, trauma, endocrine dysfunction, sympathetic overactivity, viral infection, environmental elements, psychosocial distress, and other unrecognized factors may all be independently involved through different mechanisms besides their possible or probable contributions to CS. It is possible that psychosocial distress interacts with biological factors to cause symptoms.

Should all CSS disorders be lumped together or split? There are many more similarities among them than differences, supporting the concept of group classification, as advocated by most investigators. However it is important to recognize that they are not the same diseases, and their biopathological mechanisms may vary in some aspects. In

FMS, for example, there is hyperactivity of the CRH neurons, whereas hypofunction of these neurons has been reported in CFS (168). Overlap among members of any group classification in medicine (eg, the vasculitides) does not mean *total* overlap, and this is also true of CSS disorders. The advantage of “lumping” of CSS is further described under “Significance of CSS” below.

In summary, the CSS paradigm seems an important new concept with considerable significance that deserves further exploration.

Significance of CSS

1. CSS diseases are based on both biological and psychological factors, with implications for patient and physician education and proper patient care. Thus questioning the veracity of a patient with CSS is unwarranted (236).
2. The concept of CSS will foster further research involving the CNS.
3. The recognition of mutual associations among the CSS diseases is helpful in their diagnosis and in avoiding costly and unnecessary investigations as well as surgery.
4. Since the CSS members have similar (but not the same) pathophysiological mechanisms, elucidation of a certain mechanism or treatment efficacy in 1 may apply to the others.
5. The existence of CS in an asymptomatic individual may predict symptomatic development of a CSS disease in the future.
6. The presence of CS in a disease with structural pathology, eg, RA, osteoarthritis, and SLE, would alert a physician to evaluate for a concomitant CSS condition (eg, FMS) by history and a simple TP examination (this examination would evaluate CS).
7. The copresence of a CSS condition with a disease having structural pathology would need a different management approach to avoid unnecessary and harmful medications and for successful holistic patient management.
8. The CSS as a group is probably the most common medical problem for which patients consult a physician, so that greater physician interest, academic research, and adequate funding for research are imperative.
9. The presence of multiple CSS disorders in the same patient is likely to increase CS and the burden of distress (28). So, a physician should focus and help to manage not only on the presenting symptoms, in a FMS patient as an example, but also on other associated CSS conditions, eg, IBS and RLS.
10. The effect of various drugs on CS and patient symptoms can be evaluated in the human pain laboratory by testing for CS and grading the symptoms at baseline and after clinical trials of a short duration (70,231-233) followed by longer trials. The same may also be true of nonpharmacologic therapy, eg,

sleep hygiene, exercise, cognitive behavioral therapy, and meditation.

The drugs that are known to attenuate CS are the NMDA receptor antagonists, ie, ketamine (70,231,232) and amitriptyline (233), and gabapentin (234), among others. More effective and safer drugs are likely to be developed in the future. Functional brain imaging may also be used to visualize the changes related to CS following drug and non-drug therapy (106,234). Noting that buprenorphine, an opioid, not only has an analgesic, but also an antihyperalgesic effect to electrically evoked pain, Simonet remarked that drugs that inhibit CS may be a new and beneficial way to manage chronic pain (237). Much future work is necessary to explore various aspects of CS and its relevance to CSS and other diseases.

ACKNOWLEDGMENTS

The author thanks Drs. Alfonse Masi, John Winfield, and William Maixner for their most helpful critique of the article, and Deeba Yunus for fine help with the references.

REFERENCES

1. Yunus MB. Central sensitivity syndromes: a unified concept for fibromyalgia and other similar maladies. *J Indian Rheumatism Assoc* 2000;8:27-33.
2. Yunus MB. The concept of central sensitivity syndromes. In: Wallace DJ, Clauw DJ, eds. *Fibromyalgia and Other Central Syndromes*. Philadelphia, Lippincott Williams & Wilkins, 2005;29-44.
3. Lipkin M. Functional or organic? A pointless question. *Ann Intern Med* 1969;71:1013-7.
4. Barsky AJ, Borus JF. Functional somatic syndromes. *Ann Intern Med* 1999;130:910-21.
5. Sharpe M. Medically unexplained symptoms and syndromes. *Clin Med* 2002; 501-14.
6. Escalante A, Fischbach M. Musculoskeletal manifestations, pain, and quality of life in Persian Gulf War veterans referred for rheumatologic evaluation. *J Rheumatol* 1998;25:2228-35.
7. Reid S, Hotopf M, Hull L, Ismail K, Unwin C, Wessely S. Multiple chemical sensitivity and chronic fatigue syndrome in British Gulf War veterans. *Am J Epidemiol* 2001;153:604-9.
8. Gray GC, Reed RJ, Kaiser KS, Smith TC, Gastanaga VM. Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee Health Study. *Am J Epidemiol*. 2002 Jun 1;155(11):1033-44. Erratum in *Am J Epidemiol* 2005;155:1033-4.
9. Dunphy RC, Bridgewater L, Price DD, Robinson ME, Zeilman CJ 3rd, Verne GN. Visceral and cutaneous hypersensitivity in Persian Gulf war veterans with chronic gastrointestinal symptoms. *Pain* 2003;102:79-85.
10. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. *Dig Dis Sci* 1995;40:1607-13.
11. Giesecke J, Reed BD, Haefner HK, Giesecke T, Clauw DJ, Gracely RH. Quantitative sensory testing in vulvodynia patients and increased peripheral pressure pain sensitivity. *Obstet Gynecol* 2004;104:126-33.
12. Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. *Am J Gastroenterol* 2003;98:2454-9.

13. Besson JM. The neurobiology of pain. *Lancet* 1999;35:1610-5.
14. Staud R. The neurobiology of chronic musculoskeletal pain (including chronic regional pain). In: Wallace DJ, Clauw DJ, eds. *Fibromyalgia and Other Central Pain Syndromes*. Philadelphia, Lippincott, Williams and Wilkins, 2005;45-62.
15. Cohen SA. Physiology of Pain. In: Warfield CA, Bajwa ZH, eds. *Principles and Practice of Pain Medicine*. New York, McGraw-Hill, 2004;35-48.
16. Mao JR. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. *Brain Res Rev* 1999;30:289-304.
17. Vallone D, Pichetti R, Borrelli E. Structure and function of dopamine receptors. *Neurosci Biobehav Rev* 2000;24:125-32.
18. Millan MJ. Descending control of pain. *Prog Neurobiol* 2002;66:355-474.
19. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. *Arthritis Rheum* 2005;52:2495-505.
20. Arendt-Nielsen L, Petersen-Felix, Fischer M, Bak P, Bjerring P, Zbiden AM. Effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo controlled experimental human study. *Anesth Analg* 1995;81:63-8.
21. Price DD. Psychological and neural mechanisms of the affective dimension of pain. *Science* 2000;288:1769-72.
22. Yunus MB, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. *Semin Arthritis Rheum* 1981;11:151-71.
23. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. *Ann Intern Med* 2001;134:868-81.
24. Wysenbeek AJ, Shapira Y, Leibovici L. Primary fibromyalgia and the chronic fatigue syndrome. *Rheumatol Int* 1991;10:227-9.
25. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. *Am J Med* 1992;92:363-7.
26. Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. *Arch Intern Med* 1994;154:2049-53.
27. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. *Arch Intern Med* 2000;160:221-7.
28. White KP, Speechley M, Harth M, Ostbye T. Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population. A controlled study. *Scand J Rheumatol* 2000;29:44-51.
29. Jason LA, Taylor RR, Kennedy CL. Chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivities in community-based sample of persons with chronic fatigue-like symptoms. *Psychosom Med* 2000;62:655-63.
30. Bengtsson A, Henriksson KG, Jorfeldt L, Kagedal B, Lenmarken C, Lindstrom F. Primary fibromyalgia. A clinical and laboratory study of 55 patients. *Scand J Rheumatol* 1986;15:340-7.
31. Goldenberg DL. Fibromyalgia syndrome: an emerging but controversial condition. *JAMA* 1987;257:2782-7.
32. Romano TJ. Coexistence of irritable bowel syndrome and fibromyalgia. *WV Med J* 1988;84:16-8.
33. Yunus MB, Masi AT, Aldag JC. A controlled study of primary fibromyalgia syndrome: clinical features and association with other functional syndromes. *J Rheumatol* 19(Suppl):62-71, 1989.
34. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The 1990 criteria for classification of fibromyalgia. Report of the multicenter criteria committee. *Arthritis Rheum* 1990;33:160-72.
35. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibromyalgia syndrome. *Dig Dis Sci* 1991;36:59-64.
36. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. *Arthritis Rheum* 1995;38:19-28.
37. Sivri A, Cindas A, Dincer F, Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. *Clin Rheumatol* 1996;15:283-6.
38. Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakra M, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. *Am J Gastroenterol* 1999;94:3541-6.
39. Yunus MB, Inanici F, Aldag JC, Mangold RF. Fibromyalgia in men: comparison of features with women. *J Rheumatol* 2000;27:485-90.
40. Choudhury AK, Yunus MB, Haq SA, Alam MN, Sebrina F, Aldag JC. Clinical features of fibromyalgia in a Bangladeshi population. *J Muskuloskel Pain* 2001;9:25-33.
41. Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome. *Clin Rheumatol* 2005;24:595-601.
42. Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. *Br Med J* 1996;312:1339.
43. Tayag-Kier CE, Keenan GF, Scalzi B, Elliot J, Zhao RH, Arens R. Sleep and periodic limb movement in sleep in juvenile fibromyalgia. *Pediatrics* 2000;106:E70.
44. Slotkoff AT, Radulovic DA, Clauw DJ. The relationship between fibromyalgia and the multiple chemical sensitivity syndrome. *Scand J Rheumatol* 1997;26:364-67.
45. Wallace DJ. Genitourinary manifestations of fibrositis: an increased association with the female urethral syndrome. *J Rheumatol* 1990;17:238-9.
46. Paira SO. Fibromyalgia associated with female urethral syndrome. *Clin Rheumatol* 1994;13:88-9.
47. Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndrome or post-traumatic fibromyalgia syndrome. *Semin Arthritis Rheum* 2002;32:38-50.
48. Buchwald D. Fibromyalgia and chronic fatigue syndrome: similarities and differences. *Rheum Dis Clin North Am* 1996;22:219-43.
49. Barton A, Pal B, Whorwell PJ, Marshall D. Increased prevalence of sicca complex and fibromyalgia in patients with irritable bowel syndrome. *Am J Gastroenterol* 1999;94:1898-901.
50. Hershfield NB. Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey. *Can J Gastroenterol* 2005;19:231-4.
51. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. *Gut* 1986;27:37-40.
52. Watson WC, Sullivan SN, Corke M, Rush D. Globus and headache: common symptoms of the irritable bowel syndrome. *Can Med Assoc J* 1978;118:387-8.
53. Maxton DG, Morris J, Whorwell PJ. More accurate diagnosis of irritable bowel syndrome by the use of non-colonic symptomatology. *Gut* 1991;32:784-6.
54. Peres MF, Young WB, Kaup AO, Zukerman E, Silberstein SD. Fibromyalgia is common in patients with transformed migraine. *Neurology* 2001;57:1326-8.
55. Young WB, Piovesan EJ, Biglan KM. Restless legs syndrome and drug-induced akathisia in headache patients. *CNS Spectrum* 2003;8:450-6.
56. Wright EF, Des Rosier KF, Clark MK, Bifano SL. Identifying undiagnosed rheumatic disorders among patients with TMD. *J Am Dent Assoc* 1997;128:738-44.
57. Donnay A, Ziem G. Prevalence and overlap of chronic fatigue

- syndrome and fibromyalgia syndrome among 100 new patients with multiple chemical sensitivity. *J Chronic Fatigue Syndrome* 1999;5(3/4):71-80.
58. Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. *Urology* 1997;49(Suppl A):52-7.
 59. Clauw DJ, Schmidt M, Radulovic D, Singer A, Katz P, Bresette J. The relationship between fibromyalgia and interstitial cystitis. *J Psychiat Res* 1997;31:125-31.
 60. Novi JM, Jeronis S, Srinivas S, Srinivason R, Morgan MA, Arya LA. Risk of irritable bowel syndrome and depression in women with interstitial cystitis: a case-control study. *J Urol* 2005;174:937-40.
 61. Dobie DJ, Kivlahan DR, Maynard C, Bush KR. Posttraumatic stress disorder in female veterans: association with self-reported health problems and functional impairment. *Arch Intern Med* 2004;164:394-400.
 62. Amir M, Kaplan Z, Neumann L, Sharabani R, Shani N, Buskila D. Posttraumatic stress disorder, tenderness and fibromyalgia. *J Psychosom Res* 1997;42:607-13.
 63. Granges G, Littlejohn G. Pressure pain threshold in pain-free subjects in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. *Arthritis Rheum* 1993;36:642-6.
 64. Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. *Arthritis Rheum* 2003;48:1420-9.
 65. Carli G, Suman AL, Biasi G, Marcolongo R. Reactivity to superficial and deep stimuli in patients with chronic musculoskeletal pain. *Pain* 2002;100:259-69.
 66. Lautenbacher S, Rollman GB, McCain GA. Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. *Pain* 1994;59:45-53.
 67. McDermid AJ, Rollman GB, McCain GA. Generalized hyper-vigilance in fibromyalgia: evidence of perceptual amplification. *Pain* 1996;66:133-44.
 68. Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. *Pain* 1996;68:375-83.
 69. Sorensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. hyperexcitability in fibromyalgia. *J Rheumatol* 1998;25:152-5.
 70. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. *Pain* 2000;85:483-91.
 71. Agargun MY, Takeoglu I, Gunes A, Adak B, Jra H, Ercan M. Sleep quality and pain threshold in patients with fibromyalgia. *Compr Psychiatry* 1999;40:226-8.
 72. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. *Pain* 2003;105:403-13.
 73. Geisser ME, Casey KL, Brucksch CB, Ribbens CM, Appleton BB, Crofford LJ. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. *Pain* 2003;102:243-50.
 74. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. *Pain* 2001;91:165-75.
 75. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. *Pain* 2002;99:49-59.
 76. Hurtig IM, Raak RI, Kendall SA, Gerdl B, Wahren LK. Quantitative sensory testing in fibromyalgia patients and healthy subjects. *Clin J Pain* 2001;17:316-22.
 77. Staud R, Price DD, Robinson ME, Mauderli AP, Vierck CJ. Maintenance of windup of second pain requires less frequent stimulation if fibromyalgia patients compared to normal controls. *Pain* 2004;110:689-96.
 78. Vecchiet L, Giamberardino MA, de Bigontina P, Dragani L. Comparative sensory evaluation of parietal tissue in painful and non-painful areas in fibromyalgia and myofascial pain syndrome. Proceedings of the 7th World Congress on Pain, Progress in Pain Research and Management, vol. 2, Gebhart GF, Hammond DL, Jensen TS, eds., Seattle, IASP Press, 1994;177-85.
 79. Banic B, Petersen-Felix S, Andersen OK, Radanov BP, Villiger PM, Arendt-Nielsen L. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. *Pain* 2004;107:7-15.
 80. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. *Arthritis Rheum* 2002;46:1333-43.
 81. Cook DB, Lange G, Ciccone DS, Liu WC, Strffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. *J Rheumatol* 2004;31:364-78.
 82. Montoya P, Sitges C, Garcia-Herrera M, Rodriguez-Cotes A, Izquierdo R, Truyols M, et al. Reduced brain habituation to somatosensory stimulation in patients with fibromyalgia. *Arthritis Rheum* 2006;54:1995-2003.
 83. Vecchiet L, Montanari G, Pizzigallo E, Iezzi S, de Bigontina P, Dragani L, et al. Sensory characterization of somatic parietal tissues in humans with chronic fatigue syndrome. *Neurosci Lett* 1996;208:117-20.
 84. Schwartz RB, Garada BM, Komaroff AL, Tice HM, Gleitz M, Jolesz FA, et al. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison with MR imaging and SPECT. *AJR Am J Roentgenol* 1994;162:935-41.
 85. Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, et al. Tolerance for rectosigmoid distension in irritable bowel syndrome. *Gastroenterology* 1990;98:1187-92.
 86. Munakata J, Naliboff B, Harraf F, Kodner A, Lembo T, Chang L, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. *Gastroenterology* 1997;112:55-63.
 87. Naliboff BD, Munakata J, Fullerton S, Gracely RH, Kodner A, Harraf F, et al. Evidence for two distinct perceptual alterations in irritable bowel syndrome. *Gut* 1997;41:505-12.
 88. Lembo T, Naliboff BD, Matin K, Munakata J, Parker RA, Gracely RH, et al. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. *Pain* 2000;87:137-47.
 89. Schmulson M, Chang L, Naliboff B, Lee OY, Mayer EA. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. *Am J Gastroenterol* 2000;95:152-6.
 90. Drewes AM, Petersen P, Rossel P, Gao C, Hansen JB, Arendt-Nielsen L. Sensitivity and distensibility of the rectum and sigmoid colon in patients with irritable bowel syndrome. *Scand J Gastroenterol* 2001;36:827-32.
 91. Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. *Pain* 2001;93:7-14.
 92. Rey E, Diaz-Rubio M. Prevalence of rectal hypersensitivity in patients with irritable bowel syndrome and its clinical subgroups. *Rev Esp Enferm Dig* 2002;94:247-58.
 93. Bouin M, Plourde V, Riberdy M, Lupien F, Laganier M, Verrier P, Poitras P. Rectal distension testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. *Gastroenterology* 2002;122:2075-8.
 94. Dong WZ, Zou DW, Li ZS, Zou XP, Zhu AY, Xu GM, et al. Study of visceral hypersensitivity in irritable bowel syndrome. *Chin J Dig Dis* 2004;103-9.

95. Li Y, Wang Y, Zuo X, Guo Y, Zhang H, Lu X, et al. Visceral perception thresholds after rectal thermal and pressure stimuli in irritable bowel syndrome patients. *J Gastroenterol Hepatol* 2004;19:187-91.
96. Kuiken SD, Lindeboom R, Tytgat GN, Boeckstaens GE. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. *Aliment Pharmacol* 2005;15:22:157-64.
97. Mertz H, Naliboff B, Munakata J, Niazi N. Altered rectal perception is a biologic marker of patients with irritable bowel syndrome. *Gastroenterology* 1995;109:40-52.
98. Corsetti M, Ogliaeri C, Marino B, Basilisco G. Perpetual sensitivity and response bias during rectal distension in patients with irritable bowel syndrome. *Neurogastroenterol Motil* 2005;541-7.
99. Rossel P, Drewes AM, Petersen P, Nielsen J, Arendt-Nielsen L. Pain produced by electric stimulation of the rectum in patients with irritable bowel syndrome: further evidence of visceral hyperalgesia. *Scand J Gastroenterol* 1999;34:1001-6.
100. Bouin M, Meunier P, Riberdy-Poitras M, Poitras P. Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastro-intestinal specific defect or a general systemic condition? *Dig Dis Sci* 2001;46:11:2542-8.
101. Costantini M, Sturniolo GC, Zaninotto G, D'Inca R, Polo R, Naccarato R, et al. Altered esophageal pain threshold in irritable bowel syndrome. *Dig Dis Sci* 1993;38:206-12.
102. Coffin B, Bouhassira D, Sabate J-M, Barbe L, Jian R. Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. *Gut* 2004;53:1465-70.
103. Rodrigues AC, Verne GN, Schmidt S, Mauderli AP. Hypersensitivity to cutaneous thermal nociceptive stimuli in irritable bowel syndrome. *Pain* 2005;115:5-11.
104. Nicolodi M, Sicuteri R, Coppola G, Greco E, Pietrini U, Sicuteri F. Visceral pain threshold is deeply lowered far from the head in migraine. *Headache* 1994;34:12-9.
105. Dickhaus B, Mayer EA, Firooz N, Conde F, Olivas TI, Fass R, et al. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. *Am J Gastroenterol* 2003;98:135-43.
106. Drossman DA. Brain imaging and its implications for studying centrally targeted treatments in irritable bowel syndrome: a primer for gastroenterologists. *Gut* 2005;54:569-73.
107. Schoenen J, Bottin D, Hardy F, Gerard P. Cephalic and extra-cephalic pressure pain thresholds in chronic tension-type headache. *Pain* 1991;47:145-9.
108. Langemark M, Jensen K, Jensen TS, Olesen J. Pressure pain thresholds and thermal nociceptive thresholds in chronic tension-type headache. *Pain* 1989;38:203-10.
109. Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headaches. *Arch Neurol* 1996;53:373-76.
110. Jensen R, Bendtsen L, Olesen J. Muscular factors are of importance in tension-type headache. *Headache* 1998;38:10-7.
111. Langemark M, Bach FW, Jensen TS, Olesen J. Decreased nociceptive flexion reflex threshold in chronic tension-type headache. *Arch Neurol* 1993;50:1061-4.
112. Bendtsen L, Jensen R, Olesen J. Qualitative altered nociception in chronic myofascial pain. *Pain* 1996;65:259-64.
113. de Tommaso M, Libro G, Guido M, Sciruicchio V, Losito L, Puca F. Heat pain thresholds and cerebral event-related potentials following painful CO₂ laser stimulation in chronic tension-type headache. *Pain* 2003;104:111-9.
114. Pielsticker A, Haag G, Zaudig M, Lautenbacher S. Impairment of pain inhibition in chronic tension-type headache. *Pain* 2005;118:215-23.
115. Flor H, Diers M, Birbaumer N. Peripheral and electrocutaneous responses to painful and non-painful stimulation in chronic pain patients, tension headache patients and healthy controls. *Neurosci Lett* 2004;361:147-50.
116. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. *Ann Neurol* 2000;47:614-24.
117. Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky D. Repeated noxious stimulation of the skin enhances cutaneous perception of migraine patients in-between attacks: clinical evidence for cutaneous sub-threshold increase in membrane excitability of central trigeminovascular neurons. *Pain* 2003;104:693-700.
118. de Tommaso M, Guido M, Giuseppe L, Losito L, Sciruicchio V, Monetti C, et al. Abnormal brain processing of cutaneous pain in migraine patients during the attack. *Neurosci Lett* 2002;333:29-32.
119. Vingen JV, Pareja JA, Storen O, White LR, Stovner LJ. Phonophobia in migraine. *Cephalgia* 1998;18:243-9.
120. Drummond PD. Photophobia and autonomic response to facial pain in migraine. *Brain* 1997;120:1857-64.
121. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. *J Craniomandib Disord* 1992;6:301-55.
122. Malow RM, Grimm L, Olson RE. Difference in pain perception between myofascial pain dysfunction patients and normal subjects: a signal detection analysis. *J Psychosom Res* 1980;24:303-9.
123. Svensson P, List T, Hector G. Analysis of stimulus-evoked pain in patients with myofascial temporomandibular pain disorders. *Pain* 2001;92:399-409.
124. Maixner W, Fillingim R, Booker D, Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. *Pain* 1995;63:341-51.
125. Maixner W, Fillingim R, Sigurdsson A, Kincaid S, Silva S. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain: evidence for altered temporal summation of pain. *Pain* 1998;76:71-81.
126. Fillingim RB, Fillingim LA, Hollins M, Sigurdsson A, Maixner W. Generalized vibrotactile allodynia in a patient with temporomandibular disorder. *Pain* 1998;75-8.
127. Kashima K, Rahman OIF, Sakoda S, Shiba R. Increased pain sensitivity of the upper extremities of TMD patients with myalgia to experimentally-evoked noxious stimulation: possibility of worsened endogenous opioid systems. *Cranio* 1999;17:241-6.
128. Inanici F, Yunus MB. Clinical features and psychological factors in regional soft tissue pain: comparison with fibromyalgia syndrome. *J Musculoskel Pain* 1999;7(1/2):293-301.
129. Tunks E, Crook J. Regional soft tissue pains: alias myofascial pain? *Baillieres Best Pract Res Clin Rheumatol* 1999;13:345-69.
130. Clauw DJ, Williams D, Lauerma W, Dahlman M, Aslami A, Nachemson AL, et al. Pain sensitivity as a correlate of clinical status in individuals with chronic low back pain. *Spine* 1999;24:2035-41.
131. Moog M, Quinter J, Hall T, Zusman M. The late whiplash syndrome: a psychophysical study. *Eur J Pain* 2002;6:283-94.
132. Curatolo M, Petersen-Felix, Arendt-Nielsen L, Giani C, Zbinden AM, Radanov BP. Central hypersensitivity in chronic pain after whiplash injury. *Clin J Pain* 2001;17:306-15.
133. Sterling M, Jull G, Vicenzino B, Kenardy J. Characterization of acute whiplash-associated disorders. *Spine* 2004;29:182-8.
134. Kasch J, Qerama E, Bach FW, Jensen TS. Reduced cold pressure pain tolerance in non-recovered whiplash patients: a 1-year prospective study. *Eur J Pain* 2005;9:561-9.
135. Banic B, Petersen-Felix S, Anderson OK, Radanov BP, Villiger PM, Arendt-Nielsen L. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury. *Pain* 2004;107:7-15.
136. Giesecke T, Gracely RH, Grant MA, Nachemson A, Petzke F, Williams DA, et al. Evidence of augmented central pain processing in idiopathic chronic low back pain. *Arthritis Rheum* 2004;50:613-23.

137. Stiasny-Kolster K, Magerl W, Oertel WH, Moller JC, Treede R-D. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome. *Brain* 2004;127:773-82.
138. Bara-Jimenez W, Aksu M, Graham B, Sato S, Hallett M. Periodic limb movements in sleep: state-dependent excitability of the spinal cord reflex. *Neurology* 2000;54:1609-16.
139. Tergau F, Wischer S, Paulus W. Motor system excitability in patients with restless legs syndrome. *Neurology* 1999;52:1060-3.
140. Quatralo R, Manconi M, Gastaldo E, Eleopra R, Tugnoli V, Tola MR, et al. Neurophysiological study of corticomotor pathways in restless legs syndrome. *Clin Neurophysiol* 2003;114:1638-45.
141. Bell IR, Hardin EE, Baldwin CM, Schwartz G. Increased limbic system symptomatology and sensibility of young adults with chemical and noise sensitivities. *Environ Res* 1995;70:84-97.
142. Bajaj P, Bajaj P, Madsen H, Arendt-Nielsen L. A comparison of modality-specific somatosensory changes during menstruation in dysmenorrheic and nondysmenorrheic women. *Clin J Pain* 2002;18:180-90.
143. Granot M, Yarnitsky D, Itskovitz-Eldor J, Granovsky Y, Peer E, Zimmer EZ. Pain perception in women with dysmenorrhea. *Obstet Gynecol* 2001;98:407-11.
144. Giamberardino MA, Berkley KJ, Iezzi S, de Bigontina P, Vecchiet L. Pain threshold variations in somatic wall tissues as a function of menstrual cycle, segmental site and tissue depth in non-dysmenorrheic women, dysmenorrheic women and men. *Pain* 1997;71:187-97.
145. Hapidou EG, De Catanzaro D. Sensitivity to cold pressor pain in dysmenorrheic and non-dysmenorrheic women as a function of menstrual cycle phase. *Pain* 1988;34:277-83.
146. Ness TJ, Powell-Boone T, Cannon R, Lloyd LK, Fillingim RB. Psychophysical evidence of hypersensitivity in subjects with interstitial cystitis. *J Urol* 2005;173:1983-7.
147. Friedman MJ. Neurobiologic sensitization models of post-traumatic stress disorder: their possible relevance to multiple chemical sensitivity syndrome. *Toxicol Ind Health* 1994;10:449-62.
148. Shalev AY, Peri T, Brandes D, Freedman S, Orr SP, Pitman RK. Auditory startle response in trauma survivors with posttraumatic stress disorder: a prospective study. *Am J Psychiatry* 2000;157:255-61.
149. Bremner JD, Vermetten E, Schmahl C, Vaccarino V, Vytilingam M, Afzal N, et al. Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder. *Psychol Med* 2005;35:791-806.
150. Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. *Pain* 2004;107:54-60.
151. Carroll LJ, Cassidy JD, Cote P. Depression as a risk factor for onset of an episode of troublesome neck and low back pain. *Pain* 2004;107:134-9.
152. Banks SM, Kerns RD. Explaining high rates of depression in chronic pain: a diathesis-stress framework. *Psychol Bull* 1996;119:95-110.
153. Fassbender K, Samborsky W, Kellner M, Muller W, Lautenbacher S. Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. *Clin Rheumatol* 1997;16:76-9.
154. Dickens C, McGowan L, Dale S. Impact of depression on experimental pain perception: a systematic review of the literature with meta-analysis. *Psychosom Med* 2003;65:369-75.
155. Lautenbacher S, Sperl J, Schreiber W, Krieg J-C. Relationship between clinical pain complaints and pain sensitivity in patients with depression and panic disorder. *Psychosom Med* 1999;61:822-27.
156. Bar KJ, Brehm S, Boetter MK, Boettger S, Wagner G, Sauer H. Pain perception in major depression depends on pain modality. *Pain* 2005;97:103.
157. Pinerua-Shuhaibar L, Prieto-Rincon D, Ferrer A, Bonilla E, Maixner W, Suarez-Roca H. Reduced tolerance and cardiovascular response to ischemic pain in minor depression. *J Affect Disord* 1999;56:56:119-26.
158. Suarez-Roca H, Pinerua-Shuhaibar L, Morales ME, Maixner W. Increased perception of post-ischemic paresthesias in depressed subjects. *J Psychosom Res* 2003;55:253-7.
159. Otto MW, Yeo RA, Dougher MJ. Right hemisphere involvement in depression: toward a neuropsychological theory of negative affective experiences. *Biol Psychiatry* 1987;22:1201-15.
160. Holthoff VA, Beuthien-Baumann B, Zundorf G, Triemer A, Ludecke S, Winiacki P, et al. Changes in brain metabolism associated with remission in unipolar major depression. *Acta Psychiatrica Scand* 2004;110:184-94.
161. Hudson JI, Mangweth B, Pope HG Jr, De Col C, Haussman A, Gutweniger S, et al. Family study of affective spectrum disorder. *Arch Gen Psychiatry* 2003;60:170-7.
162. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz D, Auchenbach MB, et al. Family study of fibromyalgia. *Arthritis Rheum* 2004;50:944-52.
163. Bencs RM, Cirelli C, Rattenborg NC, Tononi G. Basic science of sleep. In: Sadock BJ, Sadock VA, eds. *Kaplan and Sadock's Comprehensive Text Book of Psychiatry*. Philadelphia, Lippincott Williams and Wilkins, 2005;294-5.
164. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. *Psychosom Med* 1975;37:341-51.
165. Arana GW, Ross JB, Ornstein M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. *Arch Gen Psychiatry* 1985;42:1193-204.
166. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. *J Rheumatol* 1993;20:469-74.
167. Dinan TG, Scott LV. Anatomy of melancholic depression: focus on hypothalamic-pituitary-adrenal axis overreactivity and the role of vasopressin. *J Anat* 2005;207:259-64.
168. Neeck G, Crofford LJ. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. *Rheum Dis Clin North Am* 2000;26:989-1002.
169. Moldofsky H. Fibromyalgia, sleep disorder and chronic fatigue syndrome. *Ciba Found Symp* 1993;173:262-71; discussion 272-9.
170. Gaab J, Huster D, Peisen R, Engert V, Schadt T, Schurmeyer TH, et al. Low-dose dexamethasone suppression test in chronic fatigue syndrome and health. *Psychosom Med* 2002;64:311-8.
171. Bohmelt AH, Nater UM, Franke S, Hellhammer DH, Ehlert U. Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. *Psychosom Med* 2005;67:288-94.
172. Roy-Byrne P, Uhde TW, Post RM, King AC, Buchsbaum MS. Normal pain sensitivity in patients with panic disorder. *Psychiatry Res* 1985;14:77-84.
173. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. *Science* 2003;299:1240-3.
174. Buskila D, Neumann L. Fibromyalgia (FM) and nonarticular tenderness in relatives of patients with FM. *J Rheumatol* 1997;24:941-4.
175. Buskila D, Neumann L, Press J. Genetic factors in neuromuscular pain. *CNS Spectr* 2005;10:281-84.
176. Bondy B, Spaeth M, Offenbacher M, Glatzender K, Stratz T, Schwarz M, et al. The T102C polymorphism of the 5-HTA2-receptor gene in fibromyalgia. *Neurobiol Dis* 1999;6:433-9.
177. Pata C, Erdal E, Yazici K, Camdeviren H, Ozkaya M, Ulo O. Association of the 1438 G/A and 102TC polymorphism of the 5-HT2A receptor gene with irritable bowel syndrome 5-HT2A

- gene with irritable bowel syndrome. *J Clin Gastroenterol* 2005;38:561-6.
178. Mutlu N, Erdal ME, Herken H, Oz G, Bayazit YA. T102TC polymorphisms of the 5-HT_{2A} receptor gene may be associated with temporomandibular dysfunction. *Oral Dis* 2004;10:349-52.
 179. Juhasz G, Zsombok T, Laszik A, Gonda X, Sotonyi P, Faludi G, et al. Association analysis of 5-HTTLPR variants, 5-HT_{2A} receptor gene T102/C polymorphism and migraine. *J Neurogenet* 2003;17:231-40.
 180. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, et al. Genetic basis for individual variations in pain perception and the development of for a chronic pain condition. *Hum Mol Genet* 2005;14:153-43.
 181. Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhea predominant irritable bowel syndrome in women. *Gut* 2004;53:1452-8.
 182. Park JW, Kim JS, Lee HK, Kim YI, Lee KS. Serotonin transporter polymorphism and harm avoidance personality in chronic tension-type headache. *Headache* 2004;44:1005-9.
 183. Narita M, Nishigami N, Yamaguti K, Okado N, Watanabe Y, Kuratsune H. Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. *Biochem Biophys Res Commun* 2003;311:264-6.
 184. Lasky-su JA, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of the association between two polymorphisms in the serotonin transporter gene an affective disorders. *Am J Med Genet B Neuropsychiatry Genet* 2005;133:110-5.
 185. Smith J, Fritz EL, Kerr JR, Cleare AJ, Wessely S, Matty DL. Association of chronic fatigue syndrome with human leucocyte antigen class II alleles. *J Clin Pathol* 2005;58:860-3.
 186. Segman RH, Cooper-Kazar R, Macciardi F, Goltser T, Halfon Y, Dobroborski T, et al. Association between the dopamine transporter gene and posttraumatic stress disorder. *Mol Psychiatry* 2002;7:903-7.
 187. Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah H. Genetic linkage analysis of multicase families with fibromyalgia syndrome. *J Rheumatol* 1999;26:408-12.
 188. Arnold LM, Iyenger SK, Khan MA, Kushner I, Russell IJ, Yunus MB, et al. Genetic linkage of fibromyalgia to the serotonin receptor 2A on chromosome 13 and the HLA region of chromosome 6. *Arthritis Rheum* 2003;48(Suppl 9) (Abstract):S228-9.
 189. Ferini-Strambi L, Bonati MT, Oldani A, Aridon P, Zuccuni M, Casari G. Genetics in restless legs syndrome. *Sleep Med* 2004;5:301-4.
 190. Martinez-Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. *Semin Arthritis Rheum* 2000;29:197-9.
 191. Heitkemper M, Jarrett M, Cain KC, Burr R, Levy RL, Feld A, et al. Autonomic nervous system function in women with irritable bowel syndrome. *Dig Dis Sci* 2001;46:1276-84.
 192. Pagni M, Lucini D. Chronic fatigue syndrome: a hypothesis focusing on the autonomic nervous system. *Clin Sci (London)* 1999;96:117-25.
 193. Sforza E, Pichot V, Barthelemy JC, Haba-Rubio J, Roche F. Cardiovascular variability during periodic leg movements: a spectral analysis approach. *Clin Neurophysiol* 2005;116:1096-104.
 194. Baron R, Lavine JD, Fields HL. Causalgia and reflex sympathetic dystrophy: does the sympathetic nervous system contribute to generation of pain? *Muscle Nerve* 1999;22:678-95.
 195. Sieweke N, Birklein F, Riedl B, Neundorfer B, Handwerker HO. Patterns of hyperalgesia in complex regional pain. *Pain* 1999;80:171-7.
 196. Martinez-Lavin M. Is fibromyalgia a generalized reflex sympathetic dystrophy? *Clin Exp Rheumatol* 201;19:1-3.
 197. Heim C, Ehler U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. *Psychoneuroendocrinology* 200;25:1-35.
 198. Yunus MB. Psychological aspects of fibromyalgia syndrome: a component of the dysfunctional spectrum syndrome. *Baillieres Clin Rheumatol* 1994;8:811-37.
 199. Evengard B, Schacterle RS, Komaroff AL. Chronic fatigue syndrome: new insights and old ignorance. *J Intern Med* 1999;246:455-69.
 200. Solmaz M, Kavuk I, Sayar K. Psychological factors in the irritable bowel syndrome. *Eur J Med Res* 2003;8:549-56.
 201. Torelli P, D'Amico D. An updated review of migraine and comorbid psychiatric disorders. *Neurol Sci* 2004;25(Suppl 3):S234-5.
 202. Manfredini D, Bandettini di Poggio A, Cantini E, Dell'Osso L, Bosco M. Mood and anxiety psychopathology and temporomandibular disorder: a spectrum approach. *J Oral Rehabil* 2004;31:933-40.
 203. Winfield JB. Psychological determinants of fibromyalgia and related syndromes. *Curr Rev Pain* 2000;4:276-86.
 204. Robinson ME, Wise EA, Gagnon C, Fillingim RB, Price DD. Influences of gender role and anxiety on sex differences in temporal summation of pain. *J Pain* 2004;5:77-82.
 205. Tang J, Gibson SJ. A psychophysical evaluation of the relationship between trait anxiety, pain perception, and induced anxiety. *J Pain* 2005;6:612-9.
 206. Wolfe F. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. *Ann Rheum Dis* 1997;56:268-71.
 207. McBeth J, Macfarlane J, Benjamin S, Morris S, Silman A. The association between tender points, psychological distress and adverse childhood experiences. *Arthritis Rheum* 1999;42:1397-404.
 208. Yunus MB, Ahles TA, Aldag JC, Masi AT. Relationship of clinical features with psychological status in primary fibromyalgia. *Arthritis Rheum* 1991;34:15-21.
 209. McCarberg B, Barkin RL, Wright JA, Cronan TA, Groessl E, Schmidt SM. Tender points as predictor of distress and the pharmacologic management of fibromyalgia syndrome. *Am J Ther* 2003;10:176-92.
 210. Gracely RH, Geisser ME, Giesecke T, Grant MA, Petzke F, Williams DA, et al. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. *Brain* 2004;127(Pt 4):835-43. Epub Feb 11.
 211. Van Houdenhove B, Neerinckx E, Lysens R, Vertommen H, Van Houdenhove L, Onghena P, et al. Victimization in chronic fatigue syndrome and fibromyalgia in tertiary care: a controlled study on prevalence and characteristics. *Psychosomatics* 2001;42:21-8.
 212. Scarinci IC, McDonald J, Bradley LA. Altered pain perception and psychological features among women with gastrointestinal disorders and history of abuse: a preliminary model. *Am J Med* 1994;94:105-7.
 213. Golding JM. Sexual assault history and headache: five general population studies. *J Nerv Ment Dis* 1999;187:624-9.
 214. Fillingim RB, Edwards RR. Is self-reported childhood abuse history associated with pain perception among healthy women and men? *Clin J Pain* 2005;21:387-97.
 215. Ringel Y, Whitehead WE, Tonner BB, Diamant NE, Hu Y, Jia H, et al. Sexual and physical abuse are not associated with rectal hypersensitivity in patients with irritable bowel syndrome. *Gut* 2004;53:838-42.
 216. Fillingim RB, Maixner W, Sigurdsson A, Kincaid S. Sexual and physical abuse history in subjects with temporomandibular disorders: relationship to clinical variables, pain sensitivity, and psychologic factors. *J Orofac Pain* 1997;11:48-57.
 217. Goldenberg DL. Do infections trigger fibromyalgia? *Arthritis Rheum* 1993;36:1489-92.

218. Spiller R, Campbell E. Post-infectious irritable bowel syndrome. *Curr Opin Gastroenterol* 2006;22:13-7.
219. Yunus MB, Kalyan-Raman UP, Masi AT, Aldag JC. Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. *J Rheumatol* 1989;16:97-101.
220. McLean SA, Williams DA, Clauw DJ. Fibromyalgia after motor vehicle collision: evidence and implications. *Traffic Inj Prev* 2005;6:97-104.
221. Tishler M, Levy O, Maslakov I, Bar-Chaim S, Amit-Vazina M. Neck injury and fibromyalgia—are they really associated? *J Rheumatol* 2006;33:1183-5.
222. Bradley LA, Kersh BC, DeBerry JJ, Deutsch G, Alarcon GA, McLain DA. Lessons from fibromyalgia: abnormal pain sensitivity in knee osteoarthritis. *Novartis Found Symp* 2004;260:258-70; discussion 270-9.
223. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. *J Rheumatol* 2004;31:695-700.
224. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. *Arthritis Rheum* 1994;37:1181-8.
225. Winfield JB. Systemic lupus erythematosus and fibromyalgia. In: RG Lahita, ed. *Systemic Lupus Erythematosus*. New York, Elsevier, 2004;745-54.
226. Minderhoud IM, Oldenburg B, Wismeijer JA, van Berge Henegouwen GP, Smout AJ. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationship with quality of life and coping behavior. *Dig Dis Sci* 2004;49:469-74.
227. Chiu YH, Silman AJ, Macfarlane GJ, Ray D, Gupta A, Dickens C, et al. Poor sleep and depression are independently associated with a reduced pain threshold. Results of a population study. *Pain* 2005;115:316-21.
228. Yunus MB. Primary fibromyalgia syndrome: current concepts. *Compr Ther* 1984;10:21-8.
229. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms peripheral modulation. *J Rheumatol* 1992;19:846-50.
230. Croft P, Schollum J, Silman A. Population study of tender point counts and pain as evidence of fibromyalgia. *BMJ* 1994;309:696-9.
231. Sorensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L, Bengtsson M. Fibromyalgia—are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. *J Rheumatol* 1997;24:1615-21.
232. Hocking C, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. *Anesth Analog* 2003;97:1730-9.
233. Gobel H, Hamouz V, Hansen C, Heininger K, Hirsch S, Lindner V, et al. Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not alter pericranial muscle activity readings. *Pain* 1994;59:241-9.
234. Iannetti GD, Zambreanu L, Wise RG, Buchanan TJ, Huggins JP, Smart TS, et al. Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. *Proc Natl Acad Sci USA* 2005;102:18195-200.
235. Masi AT, White KP, Pilcher JJ. Person-centered approach to care, teaching, and research in fibromyalgia syndrome: justification from biopsychosocial perspectives in populations. *Semin Arthritis Rheum* 2002;32:71-93.
236. Bennett RB. Emerging concepts in the neurobiology of chronic pain. Evidence of abnormal sensory processing in fibromyalgia. *Mayo Clin Proc* 1999;74:385-98.
237. Simonnet G. Opioids: from analgesia to anti-hyperalgesia? *Pain* 2005;118:8-9.